Hematology/Oncology

Top Story

Oncologists, PCPs disagree on who should provide cancer survivorship care

February 5, 2016

Oncologists and primary care physicians within the same integrated health system disagreed on who should ultimately manage care for survivors of cancer, according to findings presented at the Cancer Survivorship Symposium.

This could eventually lead to cancer survivors not receiving appropriate or timely follow-up care within an integrated health system.

ABIM continues to engage physicians on MOC updates

February 5, 2016
The ABIM has announced several new efforts aimed at including internists and subspecialists in the process of improving Maintenance of Certification assessments…
In the Journals

Artificial white light as effective as daylight photodynamic therapy for actinic keratosis

February 5, 2016
Artificial white light photodynamic therapy was as effective and tolerated as daylight photodynamic therapy in men with actinic keratosis, according to study results…
In the Journals

Panobinostat combinations extends PFS in heavily pretreated, relapsed multiple myeloma

February 5, 2016
Treatment with panobinostat, bortezomib and dexamethasone significantly improved PFS in patients with relapsed and refractory multiple myeloma previously treated with…
Meeting News CoverageVideo

VIDEO: Novel prediction model accurately determines survival in gastric cancer

February 5, 2016
SAN FRANCISCO — Daniel V.T. Catenacci, MD, a GI medical oncologist at the University of Chicago, discusses a novel gastric cancer prognostic model — the…
More News Headlines »
CME

Optimizing the Management of Metastatic Melanoma: Clinical Insights for Selecting First-line Therapy

This activity is supported by an independent educational grant from Merck & Co., Inc.

The incidence of melanoma is continuing to increase worldwide. In recent years, the treatment landscape for this…
More »
Video

VIDEO: Microsatellite instability predicts enhanced response to immunotherapy

February 4, 2016
More »
Featured
CME

NSCLC Treatment on Target: Examining New Evidence and Advances

This activity is supported by educational grants from Genentech, Inc. and Merck & Co., Inc.

Globally, lung cancer is the leading cause of cancer-related deaths. Eighty-five percent of lung cancers are non-small…
More »
Current Issues
View the Current Issue
HemOnc Today
morganatic-roan